Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT06705478

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-03-31

186

Participants Needed

40

Research Sites

30 weeks

Total Duration

On this page

Sponsors

N

National Institute of Allergy and Infectious Diseases (NIAID)

Lead Sponsor

C

Cipla Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes. An optional sub-study to evaluate treatment impact on the cerebrospinal fluid (CSF) profile will be conducted in a subset of 36 participants.

CONDITIONS

Official Title

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Documented HIV-1 infection
  • Diagnosis of major depressive disorder
  • On current ART regimen for at least 90 days prior to study entry with no interruption longer than 7 consecutive days
  • No plans to change ART while on study
  • Plasma HIV-1 RNA levels less than 200 copies/mL obtained within 90 days prior to enrollment
  • Previous depression treatment allowed if last antidepressant dose was at least 4 weeks prior to entry (8 weeks for fluoxetine)
  • Laboratory values within 30 days prior to entry meeting protocol criteria
  • Negative pregnancy test for those of child-bearing potential at screening and within 2 days prior to entry
  • Use of at least one highly effective contraception method if of child-bearing potential and sexually active
Not Eligible

You will not qualify if you...

  • Active suicidality or severe major depressive disorder
  • Psychotic disorders, bipolar disorder type I or II, cyclothymic disorder, or other Axis I diagnoses interfering with the trial
  • Depressive symptoms persisting over 50% of waking hours and days for 24 months prior to entry
  • Severe or active alcohol or substance use disorder within 6 months prior to entry
  • Any acute infection within 14 days prior to entry
  • Acute or serious illness requiring systemic treatment or hospitalization within 90 days prior to entry
  • Active coronary artery disease or myocardial infarction within 180 days prior to entry
  • Presence of certain chronic inflammatory conditions (e.g., rheumatoid arthritis, lupus)
  • Immune reconstitution inflammatory syndrome or history within 180 days prior to entry
  • Unstable or advanced liver disease
  • Use of medications affecting depression or neurocognitive function within 30 days prior to entry
  • Non-HIV neurological disorders
  • Epilepsy with antiepileptic treatment
  • Untreated hepatitis C virus infection
  • Current CNS or systemic malignant tumors or opportunistic infections
  • History of treated CNS or systemic malignancy or opportunistic infection within 5 years
  • Recent treatment or diagnosis of syphilis or neurosyphilis
  • Severe chronic obstructive pulmonary disease
  • Congestive heart failure
  • Daily systemic steroid use (except testosterone)
  • Diseases causing bleeding disorders
  • Use of immunostimulant therapies or investigational ARV medications within 30 days
  • Use of immunosuppressive medications affecting study outcomes
  • Pregnancy, breastfeeding, or planning pregnancy during study
  • Allergies to study drugs
  • Use of prohibited medications at screening
  • For lumbar puncture sub-study: anticoagulant use, intracerebral mass or lesions, active CNS infection, lidocaine allergy, inability to tolerate lumbar puncture, BMI over 40 kg/m2

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 40 locations

1

Alabama CRS

Birmingham, Alabama, United States, 35222

Actively Recruiting

2

University of California, Los Angeles CARE Center CRS

Los Angeles, California, United States, 90035

Actively Recruiting

3

UCSD Antiviral Research Center CRS

San Diego, California, United States, 92103

Actively Recruiting

4

University of California, San Francisco HIV/AIDS CRS

San Francisco, California, United States, 94110

Actively Recruiting

5

Harbor University of California, Los Angeles Center CRS

Torrance, California, United States, 90502

Actively Recruiting

6

University of Colorado Hospital CRS

Aurora, Colorado, United States, 80045

Actively Recruiting

7

Whitman-Walker Institute, Inc. CRS

Washington D.C., District of Columbia, United States, 20009

Actively Recruiting

8

The Ponce de Leon Center CRS

Atlanta, Georgia, United States, 30308-2012

Actively Recruiting

9

Northwestern University CRS

Chicago, Illinois, United States, 60611

Not Yet Recruiting

10

Massachusetts General Hospital CRS (MGH CRS)

Boston, Massachusetts, United States, 02114

Actively Recruiting

11

Washington University Therapeutics (WT) CRS

St Louis, Missouri, United States, 63110-1010

Actively Recruiting

12

New Jersey Medical School Clinical Research Center CRS (Site ID 31786)

Newark, New Jersey, United States, 07103

Actively Recruiting

13

Weill Cornell Chelsea CRS

New York, New York, United States, 10010

Not Yet Recruiting

14

Columbia Physicians & Surgeons (P&S) CRS

New York, New York, United States, 10032

Not Yet Recruiting

15

Weill Cornell Uptown CRS

New York, New York, United States, 10065

Not Yet Recruiting

16

University of Rochester Adult HIV Therapeutic Strategies Network CRS

Rochester, New York, United States, 14642

Not Yet Recruiting

17

Chapel Hill CRS

Chapel Hill, North Carolina, United States, 27599-7215

Actively Recruiting

18

Greensboro CRS

Greensboro, North Carolina, United States, 27401-1020

Actively Recruiting

19

Cincinnati CRS

Cincinnati, Ohio, United States, 45267-0405

Actively Recruiting

20

Case CRS

Cleveland, Ohio, United States, 44106

Not Yet Recruiting

21

Ohio State University CRS

Columbus, Ohio, United States, 43210

Actively Recruiting

22

Penn Therapeutics CRS

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

23

University of Pittsburgh CRS

Pittsburgh, Pennsylvania, United States, 15213

Actively Recruiting

24

Vanderbilt Therapeutics (VT) CRS

Nashville, Tennessee, United States, 37204

Not Yet Recruiting

25

Houston Advancing Research Team CRS

Houston, Texas, United States, 77030

Not Yet Recruiting

26

Gaborone CRS

Gaborone, Botswana

Not Yet Recruiting

27

Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS

Rio de Janeiro, Brazil, 21040-900

Not Yet Recruiting

28

Byramjee Jeejeebhoy Medical College (BJMC) CRS

Pune, Maharashtra, India, 411001

Not Yet Recruiting

29

Moi University Clinical Research Center (MUCRC) CRS

Eldoret, Rift Valley, Kenya, 30100

Not Yet Recruiting

30

Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS

Kericho, Rift Valley, Kenya, 20200

Not Yet Recruiting

31

Blantyre CRS

Blantyre, Malawi, 265

Not Yet Recruiting

32

Nutrición-Mexico CRS

Mexico City, Tlalpan, Mexico, 14080

Not Yet Recruiting

33

Barranco CRS

Lima, Peru, 15063

Not Yet Recruiting

34

De La Salle Medical and Health Sciences Institute - Angelo King Medical Research Center (DLSMHSI-AKMRC)

Dasmariñas, Cavite, Philippines, 4114

Not Yet Recruiting

35

Durban International CRS

Mount Edgecombe, South Africa, 4302

Not Yet Recruiting

36

Thai Red Cross AIDS Research Centre (TRC-ARC) CRS

Pathum Wan, Bangkok, Thailand, 10330

Not Yet Recruiting

37

Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS

Chiang Mai, Thailand, 50200

Not Yet Recruiting

38

Joint Clinical Research Centre (JCRC)/Kampala CRS

Kampala, Uganda

Not Yet Recruiting

39

Hanoi Medical University (HMU)

Hanoi, Vietnam, 10000

Not Yet Recruiting

40

Milton Park CRS

Milton Park, Harare, Zimbabwe

Not Yet Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here